Search Results - "Rubovszky, G"

Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1 by André, F., Ciruelos, E.M., Juric, D., Loibl, S., Campone, M., Mayer, I.A., Rubovszky, G., Yamashita, T., Kaufman, B., Lu, Y.-S., Inoue, K., Pápai, Z., Takahashi, M., Ghaznawi, F., Mills, D., Kaper, M., Miller, M., Conte, P.F., Iwata, H., Rugo, H.S.

“…Activation of the phosphatidylinositol-3-kinase (PI3K) pathway via PIK3CA mutations occurs in 28%-46% of hormone receptor-positive (HR+), human epidermal…”
Get full text

Comment on ‘Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study’ by Dr Steffie L. Groenland et al by Rubovszky, G., Torday, L.

Get full text

Eight-year follow up result of the OTOASOR Trial: The Optimal Treatment Of the Axilla – Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer. A randomized, single centre, phase III, non-inferiority trial by Sávolt, Á, Péley, G, Polgár, C, Udvarhelyi, N, Rubovszky, G, Kovács, E, Győrffy, B, Kásler, M, Mátrai, Z

“…Abstract Introduction The National Institute of Oncology, Budapest conducted a single centre randomized clinical study. The OTOASOR (Optimal Treatment Of the…”
Get full text

Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial by Hitre, E, Budai, B, Takácsi-Nagy, Z, Rubovszky, G, Tóth, E, Remenár, É, Polgár, C, Láng, I

“…Background: Epidermal growth factor receptor (EGFR) is highly expressed in adenoid cystic carcinoma (ACC). The efficacy and toxicity of cetuximab with…”
Get full text

Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: A phase 2 study by Rubovszky, G, Láng, I, Ganofszky, E, Horváth, Z, Juhos, É, Nagy, T, Szabó, E, Szentirmay, Z, Budai, B, Hitre, E

“…Abstract Purpose Biliary tract cancer is rare and has dismal prognosis. Chemotherapy has its role in inoperable disease but the role of targeted agents like…”
Get full text

Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial by André, F., Ciruelos, E.M., Rubovszky, G., Campone, M., Loibl, S., Rugo, H.S., Iwata, H., Conte, P., Mayer, I.A., Kaufman, B., Yamashita, T., Lu, Y.-S., Inoue, K., Takahashi, M., Pápai, Z., Longin, A.-S., Mills, D., Wilke, C., Hirawat, S., Juric, D.

Get full text

Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla – Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer by Sávolt, Á., Péley, G., Polgár, C., Udvarhelyi, N., Rubovszky, G., Kovács, E., Győrffy, B., Kásler, M., Mátrai, Z.

“…The National Institute of Oncology, Budapest conducted a single centre randomized clinical study. The OTOASOR (Optimal Treatment Of the Axilla – Surgery Or…”
Get full text

1107 Screened versus non-screened breast cancer patients in middle Hungarian region: Comparison of survival rates by Ujhelyi, M, Savolt, A, Bidlek, M, Kovacs, E, Rubovszky, G, Nyari, T, Kenessey, I, Udvarhelyi, N, Bak, M, Matrai, Z

Get full text

Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study by Bordonaro, R., Calvo, A., Auriemma, A., Hollebecque, A., Rubovszky, G., Saunders, M.P., Pápai, Z., Prager, G., Stein, A., André, T., Argilés, G., Cubillo, A., Dahan, L., Edeline, J., Leger, C., Cattan, V., Fougeray, R., Amellal, N., Tabernero, J.

“…In preclinical studies trifluridine/tipiracil (FTD/TPI) plus oxaliplatin (Industriestrasse, Holzkirchen, Germany) sensitised microsatellite stable (MSS)…”
Get full text

76. Optimal treatment of the axilla after positive sentinel lymph node biopsy in primary invasive breast cancer patients (surgery versus radiotherapy)–OTOASOR trial: 5 years follow-up of a randomized clinical trial by Sávolt, A, Mátrai, Z, Polgár, C.S, Udvarhelyi, N, Rubovszky, G, Kovacs, E, Musonda, P, Peley, G

Get full text

151. Survival rates in patients with breast cancer diagnosed by screening in Middle Hungarian Region by Ujhelyi, M, Savolt, A, Pukancsik, D, Bidlek, M, Kovacs, E, Rubovszky, G, Nyari, T, Udvarhelyi, N, Bak, M, Matrai, Z

Get full text

PR64 Clinico-pathological following-up of very young patients with breast cancer by Szollár, A, Zaka, Z, Udvarhelyi, N, Bidlek, M, Sávolt, Á, Oláh, E, Rubovszky, G, Kásler, M, Mátrai, Z

Get full text

Learning from the longitudinal course of concurrent traumatic life events, major depression and personality disorders by Burnand, Y, Rubovszky, G, Maire, D.I

Get full text

Neoadjuvant pembrolizumab or placebo + chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2– breast cancer: Results from the phase 3 KEYNOTE-756 study by Cardoso, F., O’Shaughnessy, J., McArthur, H., Schmid, P., Cortes, J., Harbeck, N., Telli, M.L., Cescon, D.W., Fasching, P., Shao, Z., Loirat, D., Park, Y.H., Gonzalez Fernandez, M., Rubovszky, G., Im, S.A., Hui, R., Takano, T., André, F., Yasojima, H., Liu, Z., Ding, Y., Jia, L., Karantza, V., Tryfonidis, K., Bardia, A.

Get full text

342P - Alpelisib (ALP) + fulvestrant (FUL) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis by presence of visceral metastasis (VM) in the SOLAR-1 trial by Campone, M., Rugo, H.S., Rubovszky, G., André, F., Loibl, S., Iwata, H., Conte, P.F., Mayer, I., Juric, D., Yamashita, T., Lorenzo, I., Ridolfi, A., Ciruelos, E.M.

“…Approximately 40% of patients (pts) with HR+, HER2– BC have mutations (mut) in PIK3CA with hyperactivation of the PI3K pathway and relative endocrine…”
Get full text

Alpelisib (ALP) + fulvestrant (FUL) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis by presence of visceral metastasis (VM) in the SOLAR-1 trial by Campone, M., Rugo, H.S., Rubovszky, G., André, F., Loibl, S., Iwata, H., Conte, P.F., Mayer, I., Juric, D., Yamashita, T., Lorenzo, I., Ridolfi, A., Ciruelos, E.M.

Get full text

LBA12 PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer by Mayer, E.L., Gnant, M.I., DeMichele, A., Martin, M., Burstein, H., Prat, A., Rubovszky, G., Miller, K.D., Pfeiler, G., Winer, E.P., Zdenkowski, N., Anderson, D., Nowecki, Z., Loibl, S., Fohler, H., Metzger, O., Fumagalli, D., Puyana Theall, K., Fesl, C., Dueck, A.

Get full text

LBA18 Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) by André, F., Ciruelos, E.M., Juric, D., Loibl, S., Campone, M., Mayer, I., Rubovszky, G., Yamashita, T., Kaufman, B., Lu, Y-S., Inoue, K., Papai, Z., Takahashi, M., Ghaznawi, F., Mills, D., Kaper, M., Miller, M., Conte, P.F., Iwata, H., Rugo, H.S.

Get full text

342PAlpelisib (ALP) + fulvestrant (FUL) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis by presence of visceral metastasis (VM) in the SOLAR-1 trial by Campone, M, Rugo, H S, Rubovszky, G, André, F, Loibl, S, Iwata, H, Conte, P F, Mayer, I, Juric, D, Yamashita, T, Lorenzo, I, Ridolfi, A, Ciruelos, E M

“…Abstract Background Approximately 40% of patients (pts) with HR+, HER2– BC have mutations (mut) in PIK3CA with hyperactivation of the PI3K pathway and relative…”
Get full text

Evaluation of the central pedicle, modified Wise-pattern technique as a standard Level II oncoplastic breast-conserving surgery. A retrospective clinicopathological study of 190 breast cancer patients by Kelemen, P., Pukancsik, D., Újhelyi, M., Kovács, E., Stamatiou, A., Ivády, G., Kenessey, I., Kovács, T., Smanykó, V., Rubovszky, G., Kásler, M., Mátrai, Z.

Get full text